Literature DB >> 17168726

Potent adenosine A1 and A2A receptors antagonists: recent developments.

O Yuzlenko1, K Kieć-Kononowicz.   

Abstract

This review summarizes the current tendencies observed in the past 5 years in the development of A(1) and A(2A) adenosine receptor antagonists performed in various academia and industry. A(1) and A(2A) AR antagonists are as well xanthines as heteroaromatic derivatives and are most commonly 6:5 fused heteroatomic compounds. Among xanthine-based compounds, some common features could be pointed out. The recent A(1) AR ligands which show good biological profile, possess long alkyl chains in position 1 and 3 as well as bulky C(8)-substituent, while A(2A) AR antagonists with a high A(2A) AR affinity are C(8)-styryl substituted with N(1)-alkyl/alkynyl moiety or fused tricyclic xanthines possessing heteroatom(s) in the third cycle. The research in the field of heteroaromatic A(1) and A(2A) ARs antagonists impressively has a wide range. Ligands are as well non-fused monocyclic substituted compounds as fused bi- and tricyclic derivatives with the nitrogen, oxygen and sulfur heteroatoms. Most often, adenosine A(1) receptor non-xanthine antagonists are adenine-based, having substituted amino group and variable nitrogen atoms positions in the molecules. A(2A) AR ligands show good affinity when furanyl function, which is crucial for binding, is present in the fused bicyclic and tricyclic analogs. Moreover, tricyclic nitrogen containing antagonists in order to be active, frequently possess long-alkylphenyl moiety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168726     DOI: 10.2174/092986706779026093

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  9 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Adenosine and its receptors as therapeutic targets: An overview.

Authors:  Sakshi Sachdeva; Monika Gupta
Journal:  Saudi Pharm J       Date:  2012-06-23       Impact factor: 4.330

Review 3.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

4.  Dynamic Changes of Astrocytes and Adenosine Signaling in Rat Hippocampus in Post-status Epilepticus Model of Epileptogenesis.

Authors:  Siqi Hong; Tingsong Li; Yuanyuan Luo; Wenjuan Li; Xiaoju Tang; Yuanzhen Ye; Peng Wu; Qiao Hu; Li Cheng; Hengsheng Chen; Li Jiang
Journal:  Cell Mol Neurobiol       Date:  2018-05-16       Impact factor: 5.046

5.  Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones.

Authors:  Anna Drabczyńska; Tadeusz Karcz; Ewa Szymańska; Meryem Köse; Christa E Müller; Minka Paskaleva; Janina Karolak-Wojciechowska; Jadwiga Handzlik; Olga Yuzlenko; Katarzyna Kieć-Kononowicz
Journal:  Purinergic Signal       Date:  2013-04-02       Impact factor: 3.765

Review 6.  Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration.

Authors:  Jocelyn Stockwell; Elisabet Jakova; Francisco S Cayabyab
Journal:  Molecules       Date:  2017-04-23       Impact factor: 4.411

Review 7.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

8.  Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2.

Authors:  Karl Vollmann; Ramatullah Qurishi; Jörg Hockemeyer; Christa E Müller
Journal:  Molecules       Date:  2008-02-12       Impact factor: 4.411

Review 9.  Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications.

Authors:  Hamideh Zarrinmayeh; Paul R Territo
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.